Human immunodeficiency virus type 1 Gag-Pol-Vif-Nef proteins (HIV-1 Gag/Pol/Vif/Nef)

The HIV-1 Gag/Pol/Vif/Nef target represents a critical assembly of structural, enzymatic, and accessory proteins essential for the life cycle of the Human Immunodeficiency Virus type 1 (HIV-1). Gag (Group-specific antigen) provides the structural framework for viral assembly and budding, while Pol (Polymerase) encodes the vital enzymes—reverse transcriptase, integrase, and protease—required for viral replication, genome integration, and maturation [1, 4, 10]. The accessory proteins Vif (Virion infectivity factor) and Nef (Negative regulatory factor) are key to viral pathogenesis; Vif counteracts host antiviral factors like APOBEC3G, and Nef downregulates cell-surface MHC-I and CD4 to facilitate immune evasion [7, 11, 14]. This composite target is central to both established antiretroviral therapies (ART) and emerging curative strategies. While most approved drugs target the Pol enzymes, newer agents like lenacapavir target the Gag-derived capsid protein [4, 15]. Furthermore, the HIVACAT T-cell Immunogen (HTI) vaccine specifically combines conserved segments of Gag, Pol, Vif, and Nef to redirect the host's immune system toward vulnerable viral regions that are less prone to mutation [2, 5, 8]. This approach aims to achieve a functional cure by empowering the immune system to control viral replication without the need for lifelong daily medication [13].

Other names

HIV-1 structural and accessory proteinsHTI immunogenHIVACAT T-cell ImmunogenHIV-1 Gag-Pol-Vif-Nef polyprotein

Inhibition of viral enzymes (reverse transcriptase, integrase, and protease), disruption of viral capsid assembly and maturation, and induction of virus-specific T-cell mediated immune responses.